机构

• 上海药物研究所 [4]
• 金属研究所 [2]
• 合肥物质科学研究院 [1]

采集方式

• OAI收割 [7]

内容类型

• 期刊论文 [7]

发表日期

• 2022 [1]
• 2020 [2]
• 2018 [2]
• 2017 [2]

学科主题

筛选

浏览/检索结果: 共7条，第1-7条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib 期刊论文  OAI收割 BMC CANCER, 2022, 卷号: 22 作者:  Jin, Ying;  Lin, Chen;  Shi, Xun;  He, Qiong;  Yan, Junrong   |  收藏  |  浏览/下载：87/0  |  提交时间：2022/12/23 Clinical and molecular features  Efficacy and outcome  EGFR T790M mutation  Non-small-cell lung cancer  Osimertinib   Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文  OAI收割 JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026 作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong   |  收藏  |  浏览/下载：103/0  |  提交时间：2020/12/24 Alflutinib  NSCLC  EGFR T790M mutation  Efficacy  Safety   BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR(T790M) mutation 期刊论文  OAI收割 THERANOSTICS, 2020, 卷号: 10, 期号: 14, 页码: 6122-6135 作者:  Yin, Weimin;  Zhao, Yuge;  Kang, Xuejia;  Zhao, Pengfei;  Zhao, Xuhong   |  收藏  |  浏览/下载：96/0  |  提交时间：2020/07/01 brain targeting delivery  tumor-associated macrophage  non-small cell lung cancer (NSCLC)  drug resistance  tyrosine kinase inhibitors (TKI)  EGFR T790M mutation   Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFR(T790M)-Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery 期刊论文  OAI收割 SMALL, 2018, 卷号: 14, 期号: 47 作者:  Yin, Weimin;  Yu, Xiaolu;  Kang, Xuejia;  Zhao, Yuge;  Zhao, Pengfei   |  收藏  |  浏览/下载：116/0  |  提交时间：2019/01/08 antiangiogenesis  EGFR(T790M) mutation  PD-L1 nanobody  simvastatin  tumor-associated macrophage   YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M)-mutant resistance in vitro and in vivo 期刊论文  OAI收割 CANCER MEDICINE, 2018, 卷号: 7, 期号: 4, 页码: 1430-1439 作者:  Zhang, Zhang;  Zou, Jian;  Yu, Lei;  Luo, Jinfeng;  Li, Yan   |  收藏  |  浏览/下载：80/0  |  提交时间：2019/01/08 EGFR inhibitor  lung cancer  pharmacokinetic  selectively  T790M mutation   Identification of hydrazone moiety-bearing aminopyrimidines as potent antitumor agents with selective inhibition of gefitinib-resistant H1975 cancer cells 期刊论文  OAI收割 CHINESE CHEMICAL LETTERS, 2017, 卷号: 28, 期号: 5, 页码: 991-994 作者:  Qin MingZe;  Wang Lei;  Yan Shuang;  Ma JunJie;  Tian Ye   |  收藏  |  浏览/下载：49/0  |  提交时间：2021/02/02 TYROSINE KINASE INHIBITOR  LUNG-CANCER  RECEPTOR  T790M  MUTANT  MUTATION  Aminopyrimidines  EGFR T790M/L858R  Selectivity  Anti-resistance  Antiproliferative activity   Identification of hydrazone moiety-bearing aminopyrimidines as potent antitumor agents with selective inhibition of gefitinib-resistant H1975 cancer cells 期刊论文  OAI收割 CHINESE CHEMICAL LETTERS, 2017, 卷号: 28, 期号: 5, 页码: 991-994 作者:  Qin MingZe;  Wang Lei;  Yan Shuang;  Ma JunJie;  Tian Ye   |  收藏  |  浏览/下载：52/0  |  提交时间：2021/02/02 TYROSINE KINASE INHIBITOR  LUNG-CANCER  RECEPTOR  T790M  MUTANT  MUTATION  Aminopyrimidines  EGFR T790M/L858R  Selectivity  Anti-resistance  Antiproliferative activity